


AMENDMENTS TO THE CLAIMS

Please cancel without prejudice or disclaimer to resubmission in a divisional or continuation application claims 22-102 indicated as cancelled.

1. (Original) A method of treating a subject suffering from breast cancer, comprising the step of administering to said subject an Androgen Receptor Antagonist, in an amount effective to treat breast cancer in said subject.
2. (Original) The method according to claim 1, comprising administering an analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, crystal, polymorph or prodrug of said Androgen Receptor Antagonist, or any combination thereof.
3. (Original) The method of claim 1, wherein said Androgen Receptor Antagonist is an alkylating agent.
4. (Original) The method of claim 1, wherein said Androgen Receptor Antagonist is an alkylating agent which binds irreversibly to an androgen receptor.
5. (Original) The method according to claim 1, wherein said Androgen Receptor Antagonist is represented by the structure of formula I:



X is a bond, O, CH₂, NH, S, Se, PR, NO or NR;

G is O or S;

T is OH, OR, -NHCOCH₃, or NHCOR;


R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH₂F, CHF₂, CF₃, CF₂CF₃, aryl, phenyl, halogen, alkenyl or OH;

R₁ is CH₃, CH₂F, CHF₂, CF₃, CH₂CH₃, or CF₂CF₃;

R₂ is F, Cl, Br, I, CH₃, CF₃, OH, CN, NO₂, NHCOCH₃, NHCOCF₃, NHCOR, alkyl, arylalkyl, OR, NH₂, NHR, NR₂, SR;

APPLICANT(S): DALTON, James T. et al.
 SERIAL NO.: 10/760,152
 FILED: January 20, 2004
 Page 3

R_3 is F, Cl, Br, I, CN, NO_2 , COR, COOH, CONHR, CF_3 , SnR_3 , or R_3 together with the benzene ring to which it is attached forms a fused ring system represented by the structure:



Z is NO_2 , CN, COR, COOH, or CONHR;

Y is CF_3 , F, Br, Cl, I, CN, or SnR_3 ;


Q is SCN, NCS, OCN, or NCO;

n is an integer of 1-4; and

m is an integer of 1-3.

6. (Original) The method of claim 5, wherein G is O, T is OH, R_1 is CH_3 , X is O, Z is NO_2 , Y is CF_3 , and Q is NCS.

7. (Original) The method according to claim 1, wherein said Androgen Receptor Antagonist is represented by the structure of formula II.



wherein X is a bond, O, CH_2 , NH, S, Se, PR, NO or NR;

G is O or S;


R_1 is CH_3 , CH_2F , CHF_2 , CF_3 , CH_2CH_3 , or CF_2CF_3 ;

T is OH, OR, $-\text{NHCOCH}_3$, or NHCOR ;


R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH_2F , CHF_2 , CF_3 , CF_2CF_3 , aryl, phenyl, halogen, alkenyl or OH;

A is a ring selected from:

APPLICANT(S): DALTON, James T. et al.
 SERIAL NO.: 10/760,152
 FILED: January 20, 2004
 Page 4



B is a ring selected from:




wherein A and B cannot simultaneously be a benzene ring;

Z is NO₂, CN, COOH, COR, NHCOR or CONHR;

Y is CF₃, F, I, Br, Cl, CN CR₃ or SnR₃;

Q₁ is NCS, SCN, NCO or OCN;

Q₂ is a hydrogen, alkyl, halogen, CF₃, CN CR₃, SnR₃, NR₂, NHCOCH₃, NHCOCF₃, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH₃, NHCSCF₃, NHCSR NHSO₂CH₃, NHSO₂R, OR, COR, OCOR, OSO₂R, SO₂R, SR,



Q₃ and Q₄ are independently of each other a hydrogen, alkyl, halogen, CF₃, CN CR₃, SnR₃, NR₂, NHCOCH₃, NHCOCF₃, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH₃, NHCSCF₃, NHCSR NHSO₂CH₃, NHSO₂R, OR, COR, OCOR, OSO₂R, SO₂R or SR;


W₁ is O, NH, NR, NO or S; and

W₂ is N or NO.

APPLICANT(S): DALTON, James T. et al.
 SERIAL NO.: 10/760,152
 FILED: January 20, 2004
 Page 5

8. (Original) The method according to claim 7, wherein G is O, T is OH, R₁ is CH₃, X is O, Z is NO₂, Y is CF₃, and Q₁ is NCS.

9. (Original) The method according to claim 1, wherein said Androgen Receptor Antagonist is represented by the structure of formula III.



wherein X is a bond, O, CH₂, NH, S, Se, PR, NO or NR;

G is O or S;

T is OH, OR, -NHCOCH₃, or NHCOR

Z is NO₂, CN, COOH, COR, NHCOR or CONHR;

Y is CF₃, F, I, Br, Cl, CN, CR₃ or SnR₃;


Q is SCN, NCS, OCN, or NCO;

R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH₂F, CHF₂, CF₃, CF₂CF₃, aryl, phenyl, halogen, alkenyl or OH; and

R₁ is CH₃, CH₂F, CHF₂, CF₃, CH₂CH₃, or CF₂CF₃.

10. (Original) The method according to claim 9, wherein G is O, T is OH, R₁ is CH₃, X is O, Z is NO₂, Y is CF₃, and Q is NCS.


11. (Original) The method according to claim 1, wherein said Androgen Receptor Antagonist is represented by the structure of formula IV:



APPLICANT(S): DALTON, James T. et al.
SERIAL NO.: 10/760,152
FILED: January 20, 2004
Page 6

wherein X is a bond, O, CH₂, NH, S, Se, PR, NO or NR;
Z is NO₂, CN, COOH, COR, NHCOR or CONHR;
Y is CF₃, F, I, Br, Cl, CN, CR₃ or SnR₃;
Q is SCN, NCS, OCN, or NCO; and
R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH₂F, CHF₂, CF₃,
CF₂CF₃, aryl, phenyl, halogen, alkenyl or OH.

12. (Original) The method according to claim 1, wherein said Androgen Receptor Antagonist is represented by the structure of formula V:



V

13. (Original) The method according to claim 1, wherein said subject is a female subject.
14. (Original) The method according to claim 1, wherein said subject is a male subject.
15. (Original) The method according to claim 1, wherein said administering comprises administering a pharmaceutical preparation comprising said Androgen Receptor Antagonist and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, crystal, polymorph, prodrug or any combination thereof; and a pharmaceutically acceptable carrier.
16. (Original) The method according to claim 15, wherein said administering comprises intravenously, intra-arterially, or intramuscularly injecting to said subject said pharmaceutical preparation in liquid form; subcutaneously implanting in said subject a pellet containing said pharmaceutical preparation; orally administering to said subject said pharmaceutical preparation in a liquid or solid form; or topically applying to the skin surface of said subject said pharmaceutical preparation.

APPLICANT(S): DALTON, James T. et al.
SERIAL NO.: 10/760,152
FILED: January 20, 2004
Page 7

17. (Original) The method according to claim 15, wherein said pharmaceutical preparation is a pellet, a tablet, a capsule, a solution, a suspension, an emulsion, an elixir, a gel, a cream, a suppository or a parenteral formulation.
18. (Original) A method of preventing, suppressing, inhibiting or reducing the incidence of breast cancer in a subject, comprising the step of administering to said subject an Androgen Receptor Antagonist, in an amount effective to prevent, suppress, inhibit or reduce the incidence of breast cancer in said subject.
19. (Original) The method according to claim 18, comprising administering an analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, crystal, polymorph or prodrug of said Androgen Receptor Antagonist, or any combination thereof.
20. (Original) The method of claim 18, wherein said Androgen Receptor Antagonist is an alkylating agent.
21. (Original) The method of claim 18, wherein said Androgen Receptor Antagonist is an alkylating agent which binds irreversibly to an androgen receptor

Claims 22-102 (Canceled)